4.2 Review

Attention deficit hyperactivity disorder in adults

期刊

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
卷 11, 期 5, 页码 684-698

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/15622975.2010.483249

关键词

ADHD; psychosocial intervention; pharmacotherapy; side effects; genetics

资金

  1. Janssen-Cilag
  2. Lilly
  3. Medice
  4. Laboratorios Rubio

向作者/读者索取更多资源

Objective. To examine available literature regarding attention deficit hyperactivity disorder (ADHD) in adults. Methods. An electronic literature search of peer-reviewed English language articles using MEDLINE (without time limits) was undertaken. Results. Symptoms of ADHD in adults exert a substantial negative impact on daily life, including work, social life and relationships. Co-morbidities are common, further impairing quality of life. Diagnosis of adult ADHD can be difficult, as current criteria require evidence of symptom onset before the age of 7 years and impact on activities typically undertaken by children. Drug therapy is the first-line treatment for adult ADHD, particularly stimulant medication. However, methylphenidate (MPH) immediate-release tablets require three or more times daily dosing, which can impact on compliance, while demonstrating a loss of symptomatic benefit later in the day. Extended-release preparations of MPH, mixed amphetamine salts and dexamphetamine can provide symptom control for 6-12 h and the non-stimulant atomoxetine has demonstrated benefit in reducing ADHD symptoms. These therapies are generally well tolerated, but may be associated with adverse effects on the cardiovascular system, which need to be further assessed in controlled clinical trials. Psychological therapy may be beneficial in adults who continue to experience clinically significant symptoms while receiving pharmacotherapy. Conclusion. Further research in all areas of adult ADHD is urgently needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据